Skip to main content

Advertisement

Table 1 Patient characteristics.

From: Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives

Patient 1 2 3 4 5
Patient age/disease discovery (year) 55 33 63 44 43
Primary disease date April 1981 August 1985 January 1984 January 1997 August 1993
Primary disease location Right ankle Left calf Left ankle Left arm Left thorax
Clarck index III V IV III III
First recurrence date March 1988 June 1986 April 1987 January 1997 March 1998
Previous treatment for advanced
disease (before cystemustine)
None Dacarbazine Vindesine (6 cycles)
Dacarbazine Vinblastine (6 cycles)
Dacarbazine Interferon α 2a (6 cycles)
Interferon α 2a Radiotherapy None Dacarbazine (8 cycles)
Treatment start date March 1988 May 1990 August 1990 February 1997 Novembre 1998
Custemustine dose (mg/m 2 ) 90 60 90 90 60
Metastatic sites Popliteal mass Lymph node Lung Bone Lymph node Lymph node Sub-cutaneous Lung
Treatment concomitant to Cystemustine Surgery (March 1988) None None None None
Recurrence of the disease None None None None None
Date of death November 2000 Alive March 2000 Alive Alive
Disease free survival (years) 12 14 10 7 6